CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 69 enrolled
Drug / intervention
SAGE-324 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04305275
NCT04305275Phase 2Completed
CompareCT.gov

A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor

Sage Therapeutics·interventional·Posted Mar 12, 2020·Updated Apr 17, 2024

In Brief

A Phase 2 clinical trial evaluating SAGE-324 and SAGE-324 Placebo for Essential Tremor. Completed, enrolled 69 participants across 27 sites.

Detailed Summary

This is a phase 2, double-blind, placebo-controlled study to evaluate the safety and efficacy of SAGE-324 compared to placebo on upper limb (UL) tremor reduction in individuals with essential tremor (ET).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Tremor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 12, 2020
Enrollment StartMay 19, 2020
Primary CompletionFeb 1, 2021
Study CompletionFeb 15, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.3 years ago

Interventions

SAGE-324drug

SAGE-324 oral tablet

SAGE-324 Placebodrug

SAGE-324 matched placebo oral tablet